Hyderabad-Based IIL Get Regulatory Nod For Its Measles-Rubella Vaccine

Hyderabad, March 28 (Maxim News): Hyderabad-based Indian Immunologicals Limited (IIL) announced that it has received approval from Drugs Controller General of India (DGCI) and Telangana State Drug Control Administration (TSDCA) for manufacturing its Measles-Rubella (MR) Vaccine.

The MR vaccine of IIL is the outcome of the Indo-Vietnam partnership, wherein IIL has partnered with the Center for Research and Production of Vaccines and Biologicals, also called Polyvac in Vietnam.

Under the exclusive agreement, Polyvac, Vietnam will supply the Measles Vaccine component to Indian Immunologicals while the Rubella vaccine component will be produced by IIL to manufacture a combined MR vaccine. The live attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to the Universal Immunization Program (UIP) of India. The MR vaccine of IIL has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years, according to a press release. (Maxim News)

---

Next Story :

Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe.  Click to follow Indtoday’s Facebook page and Twitter and Instagram. For all the latest Hyderabad News updates